PRMT5 and hepatocellular carcinoma: As PRMT5 in tumor cells inhibited PD-L1 expression, GSK3326595 (PRMT5 inhibitor) and anti-PD-1 combination therapy was more effective than either treatment alone in murine xenograft liver tumors, a MYC-driven spontaneous HCC model, and murine melanoma models (19, 50).